CoChat

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

Open access

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Abstract

Background: People with diabetes and kidney disease have a high risk of cardiovascular events and progression of kidney disease. Sodium glucose co-transporter 2 inhibitors lower plasma glucose by reducing the uptake of filtered glucose in the kidney tubule, leading to increased urinary glucose excretion. They have been repeatedly shown to induce modest natriuresis and reduce HbA1c, blood pressure, weight, and albuminuria in patients with type 2 diabetes. However, the effects of these agents on kidney and cardiovascular events have not been extensively studied in patients with type 2 diabetes and established kidney disease. Methods: The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial aims to compare the efficacy and safety of canagliflozin ­versus placebo at preventing clinically important kidney and cardiovascular outcomes in patients with diabetes and established kidney disease. CREDENCE is a randomized, double-blind, event-driven, placebo-controlled trial set in in 34 countries with a projected duration of ∼5.5 years and enrolling 4,401 adults with type 2 diabetes, estimated glomerular filtration rate ≥30 to <90 mL/min/1.73 m 2, and albuminuria (urinary albumin:creatinine ratio >300 to ≤5,000 mg/g). The study has 90% power to detect a 20% reduction in the risk of the primary outcome (α = 0.05), the composite of end-stage kidney disease, doubling of serum creatinine, and renal or cardiovascular death. Conclusion: CREDENCE will provide definitive evidence about the effects of canagliflozin on renal (and cardiovascular) outcomes in patients with type 2 diabetes and established kidney disease. Trial Registration: EudraCT number: 2013-004494-28; ClinicalTrials.gov identifier: NCT02065791.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000484633

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 3 International Diabetes Federation: IDF Diabetes Atlas, 7th edition. Brussels, Belgium, International Diabetes Federation, 2015.

Cited by

See all 251

Metadata

Authors
Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., Levin, A., Pollock, C., Wheeler, D. C., Xie, J., Zhang, H., Zinman, B., Desai, M., Perkovic, V., & on behalf of the CREDENCE study investigators
Affiliations
  • The University of Sydney (AU)
  • Stanford Medicine (US)
  • Richard L. Roudebush VA Medical Center (US)
  • University of Chicago (US)
  • Brigham and Women's Hospital (US)
  • Janssen Research & Development (United States) (US)
  • University of Utah (US)
  • University Medical Center Groningen (NL)
  • University of British Columbia (CA)
  • University College London (GB)
  • Peking University First Hospital (CN)
  • Mount Sinai Hospital (CA)
  • UNSW Sydney (AU)
Venue
American Journal of Nephrology
Publisher
S. Karger AG
Published
2017
Volume
46
Issue
6
Pages
462-472
ISSN
  • 0250-8095 (ISSN-L)
  • 1421-9670
OpenAlex
W2772844083
Cited by
234
References
32
Citations by year
2026: 3 · 2025: 8 · 2024: 15 · 2023: 25 · 2022: 16 · 2021: 27 · 2020: 45 · 2019: 51 · 2018: 40 · 2017: 2
FWCI
33.77
Type
journal article
Language
en
Open access
Licence
Locations
  • American Journal of Nephrology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
  • Spiral (Imperial College London) (submittedVersion)
Funders
Janssen Research and Development
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
canagliflozin, SGLT2 inhibitors, type 2 diabetes, diabetic nephropathy, albuminuria, end-stage renal disease, cardiovascular outcomes, renal outcomes, CREDENCE trial, trial design, baseline characteristics
MeSH terms
Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Adult, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.